FUNDC1-induced mitophagy protects spinal cord neurons against ischemic injury

Dehui Chen,Linquan Zhou,Gang Chen,Taotao Lin,Jiemin Lin,Xin Zhao,Wenwen Li,Shengyu Guo,Rongcan Wu,Zhenyu Wang,Wenge Liu
DOI: https://doi.org/10.1038/s41420-023-01780-9
2024-01-06
Cell Death Discovery
Abstract:Local ischemia and hypoxia are the most important pathological processes in the early phase of secondary spinal cord injury (SCI), in which mitochondria are the main target of ischemic injury. Mitochondrial autophagy, also known as mitophagy, acts as a selective autophagy that specifically identifies and degrades damaged mitochondria, thereby reducing mitochondria-dependent apoptosis. Accumulating evidence shows that the mitophagy receptor, FUN14 domain-containing 1 (FUNDC1), plays an important role in ischemic injury, but the role of FUNDC1 in SCI has not been reported. In this study, we aimed to investigate whether FUNDC1 can enhance mitophagy and inhibit neuronal apoptosis in the early stage of SCI. In a rat SCI model, we found that FUNDC1 overexpression enhanced neuronal autophagy and decreased neuronal apoptosis in the early stage of injury, thereby reducing spinal cord damage. In vitro studies showed that the neuroprotective effects of FUNDC1 were achieved by inhibiting mitochondria-dependent apoptosis and improving mitochondrial function. In addition, FUNDC1 enhanced mitophagy. The protective effects of FUNDC1 against apoptosis and mitochondrial dysfunction were reversed by 3-methyladenine (3-MA), an autophagy inhibitor. Taken together, our results confirm that FUNDC1 can protect against neuronal loss after SCI by inducing mitophagy, inhibiting mitochondria-dependent apoptosis, and improving mitochondrial function.
cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to protect neurons from ischemic injury by inducing mitophagy in the early stage of spinal cord injury (SCI), and to inhibit mitochondria - dependent apoptosis, thereby improving the function of spinal cord neurons. Specifically, the study focuses on the role of FUN14 domain - containing protein 1 (FUNDC1) in this process. **Paper Background**: - Spinal cord injury (SCI) is a serious disease that can lead to temporary or permanent sensory and motor dysfunctions, and there is currently no cure. - The injury can be divided into primary and secondary injuries. Among them, secondary injury is caused by factors such as local ischemia, hypoxia, and free radical production, resulting in a complex pathological process. - Mitochondria are widely distributed in spinal cord neurons and are involved in multiple cellular processes such as ATP production, Ca²⁺ balance, ROS generation, and neuronal apoptosis. - Mitophagy is a selective autophagy that specifically identifies and degrades damaged mitochondria, reduces mitochondria - dependent apoptosis, and maintains cell health. **Research Objectives**: - To explore whether FUNDC1 can protect neurons in the early stage of SCI by enhancing mitophagy, inhibiting mitochondria - dependent apoptosis, and improving mitochondrial function. - To verify these effects and their mechanisms of FUNDC1 through in vivo and in vitro experiments. **Main Findings**: - In the rat SCI model, over - expression of FUNDC1 enhanced neuronal autophagy, reduced neuronal apoptosis, and thus alleviated spinal cord injury. - In vitro experiments showed that FUNDC1 exerted a neuroprotective effect by inhibiting mitochondria - dependent apoptosis and improving mitochondrial function. - The autophagy inhibitor 3 - methyladenine (3 - MA) reversed the protective effect of FUNDC1 on apoptosis and mitochondrial dysfunction, indicating that the protective effect of FUNDC1 is achieved by enhancing mitophagy. **Conclusion**: - Early activation of FUNDC1 can protect spinal cord neurons from ischemic injury and promote the repair process by mediating mitophagy, inhibiting the mitochondrial apoptosis pathway, and improving mitochondrial function. - These results suggest that FUNDC1 can be a potential target for the early treatment of SCI.